MedTrace Logo

Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era

NCT07720596 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1814551

Last updated 2026-07-22

No results posted yet for this study

Summary

This retrospective real-world target trial emulation uses complete Czech nationwide registry data to evaluate whether molnupiravir treatment is associated with lower COVID-19 mortality during the Omicron era. The study compares adults with confirmed acute COVID-19 treated with molnupiravir in addition to standard care versus matched controls treated with standard care without molnupiravir. Patients are followed for three months from time zero, and primary endpoints are the COVID-19 case fatality rate and all-cause mortality.

Conditions

Interventions

DRUG

Molnupiravir

800 mg of molnupiravir administered twice daily, i.e., four capsules every 12 hours for five days.

Sponsors & Collaborators

  • Institute of Health Information and Statistics of the Czech Republic

    collaborator OTHER_GOV

  • Charles University, Czech Republic

    lead OTHER

Principal Investigators

  • Dalibor Veselý, M.D. · Charles University, Prague, Third Faculty of Medicine

  • Jiří Slíva, M.D., Ph.D. · Charles University, Prague, Third Faculty of Medicine

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07720596 on ClinicalTrials.gov